Effect of colestimide on reduction of body weight and waist circumference in metabolic syndrome patients with cardiovascular risk factors

Vascular Disease Prevention

Volumn 5, Issue 3, 2008, Pages 183-189

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^a   Kosugi, Rie ^a   Aoyama, Naoyoshi ^a   Niwano, Shinichi ^a   Kurokawa, Shingo ^a   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease prevention; Colestimide; Metabolic syndrome; Obesity; Weight loss

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLESTILAN; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 48749103043     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008785133782     Document Type: Article

References (19)

1. Anderson JW, Brinkman-Kaplan VL, Lee H, Wood CL. Relationship of weight loss to cardiovascular risk factors in morbidly obese individuals. J Am Coll Nutr 1994; 13: 256-61.
2. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67.
3. Kajiyama G, Tazuma S, Yamashita G, Ochi H, Miura H. Effect of MCI-196 on biliary lipids metabolism in patients with hypercholesterolemia. Rinsho Iyaku 1996; 12: 1641-92.
4. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54: 53-8.
5. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-47.
6. Suzuki T, Oba K, Futami-Suda S, et al. Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. J Nippon Med Sch 2007; 74: 81-4.
7. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67: 1383-92.
8. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338-43.
9. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-84.
10. Pi-Sunyer FX. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Obesity 2006; 14 (Suppl 3): 135S-42S.
11. Matsuzawa Y. Metabolic syndrome - definition and diagnostic criteria in Japan. J Atheroscler Thromb 2005; 12: 301.
12. Koike K, Murakami K, Nozaki N, Sugiura K, Inoue M. Colestilan, a new bile acid-sequestering resin, reduces bodyweight in postmenopausal women who have dieted unsuccessfully. Drugs R D 2005; 6: 273-9.
13. Homma Y, Kobayashi T, Yamaguchi H, Ozawa H, Sakane H, Nakamura H. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997; 129: 241-8.
14. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Int Med 1994; 121: 416-22.
15. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296: 1703-6.
16. Urizar NL, Moore DD. GUGULIPID: a natural cholesterollowering agent. Ann Rev Nutr 2003; 23: 303-13.
17. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
18. Matsuzaki Y. Colestimide: the efficacy of a novel anion-exchange resin in cholestatic disorders. J Gastroenterol Hepatol 2002; 17: 1133-5.
19. Suzuki H, Kudo H, Ishikawa Y, Nakayama T, Suzuki S, Sakamoto S. Effects of colestimide plus Bofu-tsusho-san on plasma lipids and fatty liver in perimenopausal patients. Med Postgrad 2006; 44: 35-40.